DK174997B1 - Ikke-antibakterielle tetracyclinpræparater med anticollagennolytiske egenskaber - Google Patents

Ikke-antibakterielle tetracyclinpræparater med anticollagennolytiske egenskaber Download PDF

Info

Publication number: DK174997B1
Authority: DK; Denmark
Prior art keywords: cmt; collagenase; tetracycline; activity; composition
Prior art date: 1985-02-07

Application number

DK198600622A

Other languages

Danish (da)

English (en)

Other versions

DK62286A (da

DK62286D0 (da

Inventor

Thomas F Mcnamara

Nungavaram S Ramamurthy

Lorne M Golub

Original Assignee

Univ New York State Res Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-02-07

Filing date

1986-02-07

Publication date

2004-04-13

1986-02-07 Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found

1986-02-07 Publication of DK62286D0 publication Critical patent/DK62286D0/da

1986-08-08 Publication of DK62286A publication Critical patent/DK62286A/da

2004-04-13 Application granted granted Critical

2004-04-13 Publication of DK174997B1 publication Critical patent/DK174997B1/da

Links

239000004098 Tetracycline Substances 0.000 title claims abstract description 82
150000003522 tetracyclines Chemical class 0.000 title claims abstract description 81
235000019364 tetracycline Nutrition 0.000 title claims abstract description 80
229960002180 tetracycline Drugs 0.000 title claims description 51
229930101283 tetracycline Natural products 0.000 title claims description 50
238000002360 preparation method Methods 0.000 title claims description 10
230000000791 anti-collagenolytic effect Effects 0.000 title abstract description 9
230000000694 effects Effects 0.000 claims abstract description 61
229960002424 collagenase Drugs 0.000 claims abstract description 47
241001465754 Metazoa Species 0.000 claims abstract description 30
239000000203 mixture Substances 0.000 claims abstract description 29
230000000844 anti-bacterial effect Effects 0.000 claims abstract description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
230000001965 increasing effect Effects 0.000 claims abstract description 13
208000028169 periodontal disease Diseases 0.000 claims abstract description 5
206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 3
102000029816 Collagenase Human genes 0.000 claims description 44
108060005980 Collagenase Proteins 0.000 claims description 44
241000700159 Rattus Species 0.000 claims description 35
206010012601 diabetes mellitus Diseases 0.000 claims description 30
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 21
230000001580 bacterial effect Effects 0.000 claims description 18
229960000282 metronidazole Drugs 0.000 claims description 18
238000000338 in vitro Methods 0.000 claims description 13
201000010099 disease Diseases 0.000 claims description 11
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims description 6
230000037396 body weight Effects 0.000 claims description 6
230000011382 collagen catabolic process Effects 0.000 claims description 6
210000000265 leukocyte Anatomy 0.000 claims description 5
230000001747 exhibiting effect Effects 0.000 claims description 3
206010064996 Ulcerative keratitis Diseases 0.000 claims description 2
239000002775 capsule Substances 0.000 claims description 2
239000008187 granular material Substances 0.000 claims description 2
230000001939 inductive effect Effects 0.000 claims description 2
239000011159 matrix material Substances 0.000 claims 2
239000008365 aqueous carrier Substances 0.000 claims 1
238000002651 drug therapy Methods 0.000 claims 1
230000002500 effect on skin Effects 0.000 claims 1
210000000224 granular leucocyte Anatomy 0.000 claims 1
230000000977 initiatory effect Effects 0.000 claims 1
239000007937 lozenge Substances 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
231100000444 skin lesion Toxicity 0.000 claims 1
206010040882 skin lesion Diseases 0.000 claims 1
239000007787 solid Substances 0.000 claims 1
239000003826 tablet Substances 0.000 claims 1
229940040944 tetracyclines Drugs 0.000 abstract description 32
230000003115 biocidal effect Effects 0.000 abstract description 24
239000003795 chemical substances by application Substances 0.000 abstract description 13
102000008186 Collagen Human genes 0.000 abstract description 12
108010035532 Collagen Proteins 0.000 abstract description 12
102000004190 Enzymes Human genes 0.000 abstract description 12
108090000790 Enzymes Proteins 0.000 abstract description 12
229920001436 collagen Polymers 0.000 abstract description 12
229940088598 enzyme Drugs 0.000 abstract description 12
235000019728 animal nutrition Nutrition 0.000 abstract description 3
230000004584 weight gain Effects 0.000 abstract description 3
235000019786 weight gain Nutrition 0.000 abstract description 3
210000000988 bone and bone Anatomy 0.000 abstract 1
201000007717 corneal ulcer Diseases 0.000 abstract 1
230000006378 damage Effects 0.000 abstract 1
230000007812 deficiency Effects 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
238000010348 incorporation Methods 0.000 abstract 1
208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 25
230000000845 anti-microbial effect Effects 0.000 description 16
FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
238000001727 in vivo Methods 0.000 description 9
229960004023 minocycline Drugs 0.000 description 9
239000003242 anti bacterial agent Substances 0.000 description 7
229940088710 antibiotic agent Drugs 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000011575 calcium Substances 0.000 description 5
239000000284 extract Substances 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
235000014347 soups Nutrition 0.000 description 5
239000011550 stock solution Substances 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
239000000654 additive Substances 0.000 description 4
239000004599 antimicrobial Substances 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
239000000758 substrate Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
241000282849 Ruminantia Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
208000025865 Ulcer Diseases 0.000 description 3
230000009471 action Effects 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
244000309466 calf Species 0.000 description 3
125000002837 carbocyclic group Chemical group 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
230000003511 endothelial effect Effects 0.000 description 3
210000004195 gingiva Anatomy 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000003902 lesion Effects 0.000 description 3
230000007774 longterm Effects 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
244000005706 microflora Species 0.000 description 3
230000001937 non-anti-biotic effect Effects 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
241000193755 Bacillus cereus Species 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
208000012868 Overgrowth Diseases 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
206010067868 Skin mass Diseases 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
235000015278 beef Nutrition 0.000 description 2
230000008859 change Effects 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
235000013330 chicken meat Nutrition 0.000 description 2
230000003366 colagenolytic effect Effects 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
230000000593 degrading effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000001627 detrimental effect Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
229910021645 metal ion Inorganic materials 0.000 description 2
238000000034 method Methods 0.000 description 2
244000005700 microbiome Species 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
230000003239 periodontal effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
229960001052 streptozocin Drugs 0.000 description 2
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
GTBXZWADMKOZQJ-UHFFFAOYSA-N 1-phenanthrol Chemical compound C1=CC2=CC=CC=C2C2=C1C(O)=CC=C2 GTBXZWADMKOZQJ-UHFFFAOYSA-N 0.000 description 1
208000002679 Alveolar Bone Loss Diseases 0.000 description 1
101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
235000016068 Berberis vulgaris Nutrition 0.000 description 1
241000335053 Beta vulgaris Species 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
102100028203 Cytochrome c oxidase subunit 3 Human genes 0.000 description 1
206010014989 Epidermolysis bullosa Diseases 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102000013382 Gelatinases Human genes 0.000 description 1
108010026132 Gelatinases Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
101000861034 Homo sapiens Cytochrome c oxidase subunit 3 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
208000005888 Periodontal Pocket Diseases 0.000 description 1
241000286209 Phasianidae Species 0.000 description 1
241000287531 Psittacidae Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
206010040844 Skin exfoliation Diseases 0.000 description 1
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003367 anti-collagen effect Effects 0.000 description 1
229940127090 anticoagulant agent Drugs 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000013351 cheese Nutrition 0.000 description 1
239000013522 chelant Substances 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
239000002442 collagenase inhibitor Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
229960003722 doxycycline Drugs 0.000 description 1
HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000010408 film Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
230000000409 histolytic effect Effects 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
230000003345 hyperglycaemic effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
229940110254 minocin Drugs 0.000 description 1
230000018791 negative regulation of catalytic activity Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000001019 normoglycemic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
239000004632 polycaprolactone Substances 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
244000144977 poultry Species 0.000 description 1
235000013594 poultry meat Nutrition 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
230000003068 static effect Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
229940063678 vibramycin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Fodder In General (AREA)

DK198600622A 1985-02-07 1986-02-07 Ikke-antibakterielle tetracyclinpræparater med anticollagennolytiske egenskaber DK174997B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US69904885		1985-02-07
US06/699,048 US4704383A (en)	1983-12-29	1985-02-07	Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same

Publications (3)

Publication Number	Publication Date
DK62286D0 DK62286D0 (da)	1986-02-07
DK62286A DK62286A (da)	1986-08-08
DK174997B1 true DK174997B1 (da)	2004-04-13

Family

ID=24807719

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK198600622A DK174997B1 (da)	1985-02-07	1986-02-07	Ikke-antibakterielle tetracyclinpræparater med anticollagennolytiske egenskaber

Country Status (12)

Country	Link
US (1)	US4704383A (fr)
EP (1)	EP0195906B1 (fr)
JP (1)	JP2676080B2 (fr)
AT (1)	ATE81460T1 (fr)
AU (1)	AU583884B2 (fr)
CA (1)	CA1297410C (fr)
DE (1)	DE3686956T2 (fr)
DK (1)	DK174997B1 (fr)
ES (1)	ES8708182A1 (fr)
GR (1)	GR860333B (fr)
IE (1)	IE58813B1 (fr)
ZA (1)	ZA86838B (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE34656E (en) *	1983-12-29	1994-07-05	The Research Foundation Of State University Of New York	Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
GR861167B (en) *	1985-05-02	1986-09-30	Research Corp	Bone targeted inhibitors of carbonic anhydrase
JP3016587B2 (ja) *	1989-12-04	2000-03-06	ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク	非ステロイド抗炎症剤及びテトラサイクリンの配合
US5308839A (en) *	1989-12-04	1994-05-03	The Research Foundation Of State University Of New York	Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
US5045538A (en) *	1990-06-28	1991-09-03	The Research Foundation Of State University Of New York	Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
US5770588A (en) *	1991-02-11	1998-06-23	The Research Foundation Of State University Of New York	Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5223248A (en) *	1991-02-11	1993-06-29	The Research Foundation Of State University Of New York	Non-antibacterial tetracycline compositions possessing antiplaque properties
CA2094874C (fr) *	1992-04-27	2003-02-11	Thomas F. Mcnamara	Compositions de tetracycline non-antibacteriennes possedant des proprietes anti-plaque
US5258371A (en) *	1992-05-29	1993-11-02	Kuraray Co., Ltd.	Method to reduce connective tissue destruction
US5700485A (en)	1992-09-10	1997-12-23	Children's Medical Center Corporation	Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5922340A (en)	1992-09-10	1999-07-13	Children's Medical Center Corporation	High load formulations and methods for providing prolonged local anesthesia
DK0659073T3 (da) *	1992-09-10	2002-03-11	Childrens Medical Center	Bionedbrydelige polymermatrixer med vedvarerende afgivelse af lokalanæstetika
US6043231A (en) *	1993-03-02	2000-03-28	The Research Foundation Of State Univ. Of New York	Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5523297A (en) *	1993-03-02	1996-06-04	The Research Foundation Of State University Of New York	Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US6140099A (en) *	1994-05-20	2000-10-31	The Trustees Of The University Of Pennsylvania	Method of delaying fetal membrane rupture by inhibiting matrix metalloproteinase-9 activity
US5641636A (en) *	1994-05-20	1997-06-24	University Of Pennsylvania	Method of predicting fetal membrane rupture based on matrix metalloproteinase-9 activity
MX9700850A (es)	1995-06-09	1997-09-30	Euro Celtique Sa	Formulaciones y metodos para proporcionar anestesia local prolongada.
CA2260750C (fr)	1996-06-24	2004-11-09	Euro-Celtique, S.A.	Methodes sures d'anesthesie locale
US5827840A (en) *	1996-08-01	1998-10-27	The Research Foundation Of State University Of New York	Promotion of wound healing by chemically-modified tetracyclines
US6046187A (en)	1996-09-16	2000-04-04	Children's Medical Center Corporation	Formulations and methods for providing prolonged local anesthesia
US5773430A (en) *	1997-03-13	1998-06-30	Research Foundation Of State University Of New York	Serine proteinase inhibitory activity by hydrophobic tetracycline
JP2908375B2 (ja) *	1997-04-01	1999-06-21	ザリサーチファンデーションオブステートユニバーシティオブニューヨーク	非抗バクテリア性テトラサイクリン組成物
EP1009390A4 (fr)	1997-07-02	2004-05-06	Euro Celtique Sa	Anesthesie a effet prolonge injectee dans les interlignes articulaires et corporelles
WO1999009982A1 (fr)	1997-08-25	1999-03-04	Harold Brem	Inhibiteurs d'angiogenese utilises pour prevenir des adherences et la formation de cicatrices excessives
PT1041991E (pt) *	1997-12-19	2008-10-03	Univ New York	Tetraciclinas não antibacterianas para o tratamento de esclerose múltipla
DK1053000T3 (da) *	1998-02-13	2008-09-01	Nutramax Lab Inc	Midler og fremgangsmåder til beskyttelse, behandling og udbedring af bindevæv
US6277061B1 (en) *	1998-03-31	2001-08-21	The Research Foundation Of State University Of New York	Method of inhibiting membrane-type matrix metalloproteinase
RU2202340C2 (ru) *	1998-05-27	2003-04-20	Юроселтик С.А.	Система доставки лекарства
US6015804A (en) *	1998-09-11	2000-01-18	The Research Foundation Of State University Of New York	Method of using tetracycline compounds to enhance interleukin-10 production
US5998390A (en) *	1998-09-28	1999-12-07	The Research Foundation Of State University Of New York	Combination of bisphosphonate and tetracycline
US6506740B1 (en) *	1998-11-18	2003-01-14	Robert A. Ashley	4-dedimethylaminotetracycline derivatives
US6946453B2 (en)	1998-11-18	2005-09-20	Collagenex Pharmaceuticals, Inc.	4-dedimethylaminotracycline derivatives
US7300667B1 (en)	1999-05-27	2007-11-27	Euro-Celtique, S.A.	Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
US6294694B1 (en)	1999-06-04	2001-09-25	Wisconsin Alumni Research Foundation	Matrix metalloproteinase inhibitors and method of using same
US6673843B2 (en) *	1999-06-30	2004-01-06	Emory University	Curcumin and curcuminoid inhibition of angiogenesis
US20020132798A1 (en)	2000-06-16	2002-09-19	Nelson Mark L.	7-phenyl-substituted tetracycline compounds
US7211267B2 (en)	2001-04-05	2007-05-01	Collagenex Pharmaceuticals, Inc.	Methods of treating acne
AU2002256092C1 (en) *	2001-04-05	2009-10-15	Collagenex Pharmaceuticals, Inc.	Controlled delivery of tetracycline compounds and tetracycline derivatives
US20060194773A1 (en) *	2001-07-13	2006-08-31	Paratek Pharmaceuticals, Inc.	Tetracyline compounds having target therapeutic activities
EP2329826A1 (fr)	2001-07-13	2011-06-08	Paratek Pharmaceuticals, Inc.	Tetracyclines pour le traitement de la sclérose en plaques
RU2300380C2 (ru) *	2001-10-05	2007-06-10	Тетрадженекс Фармасьютикалс, Инк.	Производные тетрациклина и способы их применения
EP2311799A1 (fr)	2002-01-08	2011-04-20	Paratek Pharmaceuticals, Inc.	Composés de tétracycline 4-dedimethylamino
US20090011991A1 (en) *	2002-03-08	2009-01-08	Emory University	Novel Curcuminoid-Factor VIIA Constructs as Suppressors of Tumor Growth and Angiogenesis
JP2005526754A (ja)	2002-03-08	2005-09-08	パラテックファーマシューティカルズインコーポレイテッド	アミノメチル置換されたテトラサイクリン化合物
EP1572078A4 (fr) *	2002-03-08	2006-08-09	Univ Emory	NOUVELLES CONSTRUCTIONS DE FACTEURS VIIa DE CURCUMINOIDES UTILISEES EN TANT QUE SUPPRESSEURS DE LA CROISSANCE TUMORALE ET DE L'ANGIOGENESE
KR101083498B1 (ko)	2002-03-21	2011-11-16	파라테크 파마슈티컬스, 인크.	치환된 테트라시클린 화합물
WO2003082011A1 (fr) *	2002-03-29	2003-10-09	The Research Foundation Of State University Of New York	Utilisation d'analogues de tetracycline non-antibacteriens et leurs formulations dans le traitement des exotoxines bacteriennes
CA2492273C (fr)	2002-07-12	2013-02-05	Paratek Pharmaceuticals, Inc.	Composes de tetracycline substituee en 3, 10, et 12a
WO2004054509A2 (fr) *	2002-12-13	2004-07-01	The Research Foundation Of State University Of New York	Tetracyclines en tant qu'agents antifongiques pour le traitement de la teigne
ES2534827T3 (es) *	2003-04-07	2015-04-29	Supernus Pharmaceuticals, Inc.	Formulaciones de tetraciclinas en dosis única diaria
JP4738333B2 (ja)	2003-07-09	2011-08-03	パラテックファーマシューティカルズインコーポレイテッド	９−アミノメチルテトラサイクリン化合物のプロドラッグ
CA2531728A1 (fr)	2003-07-09	2005-02-03	Paratek Pharmaceuticals, Inc.	Composes de tetracycline substitues
NZ547628A (en) *	2003-11-06	2010-07-30	Univ New York State Res Found	Methods of treating eczema
CA2553510C (fr) *	2004-01-15	2012-09-25	Paratek Pharmaceuticals, Inc.	Derives a cycle aromatique a provenant de composes de tetracycline
AU2005299294B2 (en)	2004-10-25	2012-06-07	Paratek Pharmaceuticals, Inc.	4-aminotetracyclines and methods of use thereof
EP2269985A3 (fr)	2004-10-25	2011-09-21	Paratek Pharmaceuticals, Inc.	Composés de tetracycline substitués
BRPI0602372B8 (pt)	2006-05-18	2021-06-22	Einco Biomaterial Ltda	processo de preparação de compósitos em base de biocerâmicas e polímeros biodegradáveis e produto derivado
PT2120963T (pt)	2006-12-21	2018-12-17	Paratek Pharm Innc	Compostos tetraciclina substituídos para tratamento de distúrbios inflamatórios da pele
PL2109602T3 (pl) *	2006-12-21	2014-09-30	Paratek Pharm Innc	Pochodne tetracyliny do leczenia zakażeń bakteryjnych, wirusowych i pasożytniczych
JP2010525069A (ja) *	2007-04-27	2010-07-22	パラテックファーマシューティカルズインコーポレイテッド	アミノアルキルテトラサイクリン化合物の合成方法および精製方法
BRPI0823405A2 (pt) *	2007-07-06	2012-12-25	Paratek Pharmaceuticals, Inc.	mÉtodos para sintetizar compostos de tetraciclina substituÍda
TW202216656A (zh)	2008-05-19	2022-05-01	美商ＰｒｔｋＳｐｖ２公司	四環素化合物之甲苯磺酸鹽及同素異形體
PT2323972E (pt)	2008-08-08	2013-10-09	Tetraphase Pharmaceuticals Inc	Compostos de tetraciclina substituídos com c7-flúor
EP2427425B1 (fr)	2009-05-08	2017-03-08	Tetraphase Pharmaceuticals, Inc.	Composés de tétracycline
IN2012DN02502A (fr)	2009-08-28	2015-08-28	Tetraphase Pharmaceuticals Inc
TWI592390B (zh)	2010-03-31	2017-07-21	四相製藥公司	聚環狀四環素化合物
MY186510A (en) *	2012-05-21	2021-07-23	Univ Nat Taiwan	Methods for drug screen using zebrafish model and the compounds screened therefrom
BR112015004523B1 (pt)	2012-08-31	2020-08-04	Tetraphase Pharmaceuticals, Inc	Compostos de tetraciclina, composições farmacêuticas e seus usos
CN110582486B (zh)	2016-10-19	2024-01-12	四相制药公司	艾若威四环素的结晶形式
US12570604B2 (en)	2018-11-09	2026-03-10	Tetraphase Pharmaceuticals, Inc.	Polymorphic forms of a tetracycline compound and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB787882A (en) *	1955-01-26	1957-12-18	Lepetit Spa	Desdimethylaminotetracyclines and pharmaceutical preparations containing same
US2895880A (en) *	1955-05-13	1959-07-21	Smith Kline French Lab	Sustained release pharmaceutical product
GB925282A (en) *	1960-05-04	1963-05-08	Lepetit Spa	Fermentation process for the production of demethyltetracycline
US3304227A (en) *	1965-07-15	1967-02-14	Loyal E Loveless	Antibiotic-containing animal feed
US3636202A (en) *	1968-02-12	1972-01-18	Lewis A Klein	Treatment of rheumatoid arthritis and related diseases
US4371465A (en) *	1981-10-07	1983-02-01	American Home Products Corporation	Mammalian collagenase inhibitors
US4454110A (en) *	1982-05-24	1984-06-12	Forsyth Dental Infirmary For Children	Self-gelling liquid composition for topical application in the oral cavity

1985
- 1985-02-07 US US06/699,048 patent/US4704383A/en not_active Expired - Lifetime
1986
- 1986-01-21 CA CA000500004A patent/CA1297410C/fr not_active Expired - Lifetime
- 1986-02-04 AU AU52984/86A patent/AU583884B2/en not_active Expired
- 1986-02-04 GR GR860333A patent/GR860333B/el unknown
- 1986-02-05 ZA ZA86838A patent/ZA86838B/xx unknown
- 1986-02-05 IE IE33386A patent/IE58813B1/en not_active IP Right Cessation
- 1986-02-06 DE DE8686101528T patent/DE3686956T2/de not_active Expired - Lifetime
- 1986-02-06 EP EP86101528A patent/EP0195906B1/fr not_active Expired - Lifetime
- 1986-02-06 ES ES551701A patent/ES8708182A1/es not_active Expired
- 1986-02-06 AT AT86101528T patent/ATE81460T1/de not_active IP Right Cessation
- 1986-02-07 DK DK198600622A patent/DK174997B1/da not_active IP Right Cessation
- 1986-02-07 JP JP61026651A patent/JP2676080B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU583884B2 (en)	1989-05-11
EP0195906A2 (fr)	1986-10-01
DK62286A (da)	1986-08-08
IE58813B1 (en)	1993-11-17
JPS61243023A (ja)	1986-10-29
DK62286D0 (da)	1986-02-07
GR860333B (en)	1986-06-13
ATE81460T1 (de)	1992-10-15
DE3686956D1 (de)	1992-11-19
AU5298486A (en)	1986-08-14
ES8708182A1 (es)	1987-10-01
CA1297410C (fr)	1992-03-17
EP0195906A3 (en)	1988-10-19
US4704383A (en)	1987-11-03
ZA86838B (en)	1986-10-29
ES551701A0 (es)	1987-10-01
DE3686956T2 (de)	1993-05-06
EP0195906B1 (fr)	1992-10-14
JP2676080B2 (ja)	1997-11-12
IE860333L (en)	1986-08-07

Legal Events

Date	Code	Title	Description
2006-02-27	PUP	Patent expired

Publication	Publication Date	Title
DK174997B1 (da)	2004-04-13	Ikke-antibakterielle tetracyclinpræparater med anticollagennolytiske egenskaber
US4935412A (en)	1990-06-19	Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4935411A (en)	1990-06-19	Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4666897A (en)	1987-05-19	Inhibition of mammalian collagenolytic enzymes by tetracyclines
AU2017201670B2 (en)	2018-12-20	A composition comprising an antibiotic and a dispersant or an anti-adhesive agent
Golub et al.	1985	Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources
JP3016587B2 (ja)	2000-03-06	非ステロイド抗炎症剤及びテトラサイクリンの配合
WO1984001895A1 (fr)	1984-05-24	Renforcement de l'activite de la tetracycline
AU2014266266A1 (en)	2016-01-28	Preventive or therapeutic agent for ruminant animal mastitis
US3567821A (en)	1971-03-02	Medicament for the affections of mucous membranes
EP0871438B1 (fr)	2008-02-27	Utilisation d'acides alpha-hydroxy dans la preparation d'un medicament pour le traitement de l'inflammation
Smith et al.	1945	The influence of streptomycin and streptothricin on the intestinal flora of mice
EP1906754A2 (fr)	2008-04-09	Nouveaux complements destines aux volailles et au betail
JP2908375B2 (ja)	1999-06-21	非抗バクテリア性テトラサイクリン組成物
JP2676093B2 (ja)	1997-11-12	動物飼料組成物
JP2801178B2 (ja)	1998-09-21	動物飼料組成物
EP0118968B1 (fr)	1986-12-03	Utilisation de l'avilamycine pour le contrôle de la dysenterie du porc
JPH0449234A (ja)	1992-02-18	豚赤痢予防，治療剤
HK1185015B (en)	2017-01-20	A composition comprising an antibiotic and a dispersant
HK1220911B (en)	2021-05-14	A composition comprising a non-peptide antibiotic and cysteamine